Premium
The Virginia Tech Center for Drug Discovery and the Virginia Drug Discovery Consortium
Author(s) -
Kingston David George Ian
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.lb485
Subject(s) - virginia tech , commonwealth , library science , west virginia , drug discovery , work (physics) , medicine , political science , engineering , geography , computer science , archaeology , mechanical engineering , bioinformatics , law , biology
This poster presents the work of two Virginia‐based drug discovery centers. The Virginia Tech Center for Drug Discovery, or VTCDD, was established in 2011 to bring together the expertise of scientists from several different departments at Virginia Tech with the mission to continue the growth and advance the stature of the existing drug discovery and development programs of the university. It operates as a “virtual center” with a small screening laboratory and a modest budget, but it has been successful in catalyzing several research collaborations and increasing grant funding. Two VTCDD members have drugs in clinical trials based on earlier work, and other members have developed new drug formulations and new drug candidates. The presentation will summarize the work of several VTCDD members. The Virginia Drug Discovery Consortium (VDDC) is a new Consortium between the major research universities in Virginia, including the University of Virginia, Virginia Commonwealth University, Virginia Tech, and the Virginia Tech Carilion Research Institute. Its initial focus is on diseases of the brain, and it has planned a BrainRx Symposium in Richmond, Virginia, for May 23–24 to promote this collaborative research focus. Details of this Symposium will be presented. Support or Funding Information Support of VTCDD by the Fralin Institute for Life Sciences at Virginia Tech is gratefully acknowledged